On February 26, 2022, the listing meeting of China's original CDK4/6 inhibitor Darsili (iReseon), independently developed by Hengrui Pharmaceutical, was held in 13 cities across the country, with the main venues in Shanghai, Beijing and Guangzhou, and 10 sub-venues including Harbin, Shijiazhuang, Nanjing, Shenyang, Tianjin, Zhengzhou, Changsha, Xi'an, Jinan and Chengdu.
Academician Xu Binghe of cancer hospital of Chinese Academy of Medical Sciences, Professor Jiang Zefei of PLA General Hospital, Professor Yin Yongmei of Jiangsu Provincial People's Hospital, Professor Wang Xiaojia of Affiliated Cancer Hospital of University of Chinese Academy of Sciences, Professor Liu Qiang of Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Professor Wang Shusen of Cancer Prevention and Control Center of Sun Yat-sen University, Professor Ma Fei of Cancer Hospital of Chinese Academy of Medical Sciences, Professor Zhang Pin of Cancer Hospital of Chinese Academy of Medical Sciences, Professor Yu Keda of Fudan University Affiliated Cancer Hospital, Professor Li Qiao of Cancer Hospital of Chinese Academy of Medical Sciences, Professor Chen Qianjun of Guangdong Provincial Hospital of Traditional Chinese Medicine and other experts attended the main venue.
Professor Zhang Qingyuan of the Affiliated Cancer Hospital of Harbin Medical University, Professor Geng Cuizhi of the Fourth Hospital of Hebei Medical University, Professor Feng Jifeng of Jiangsu Provincial Cancer Hospital, Professor Jin Feng of the First Affiliated Hospital of China Medical University, Professor Teng Yue'e of the First Affiliated Hospital of China Medical University, Professor Tong Zhongsheng of the Cancer Hospital of Tianjin Medical University, Professor Liu Zhenzhen of Henan Provincial Cancer Hospital, Professor Ouyang Zhichang of Hunan Provincial Cancer Hospital, Professor Chen Gannong of the Second Xiangya Hospital of Central South University, Professor Ling Rui of Xijing Hospital of Air Force Military Medical University, Professor Wang Haibo of the Affiliated Hospital of Qingdao University and Professor Luo Ting of West China Hospital of Sichuan University attended the sub-venue. Professor Shao Zhimin, Professor Wu Jiong and Professor Hu Xichun of Fudan University Affiliated Cancer Hospital attended the meeting by video.
Well-known scholars in the industry and breast cancer experts from all over the country gathered at the grand event through offline and online forms to witness the listing of Darxili, a CDK4/6 inhibitor independently developed by Hengrui Pharmaceutical, to talk about the new situation of breast cancer treatment and seek a new future for breast cancer treatment.
Taking Darsili's "Gestation-Budding-Birth-Growth-Companionship" as the logical line, the listing meeting told the process of CDK4/6 inhibitor Darxili's project establishment, research and development and listing, presented the strategic layout of Hengrui Pharmaceutical in the field of breast cancer, and showed hengrui Pharmaceutical's industry responsibility based in China and going to the world.
Ten years of grinding a sword, focusing on patient needs to promote research and development
At the beginning of the meeting, through the dawn of the first short drama, the R&D team led by Zhang Lianshan, deputy general manager of Hengrui Pharmaceutical, reviewed the original intention of the project for Darsili. "The first way of water, two kinds of tea, three ways of four ways is the essence", reflecting that Hengrui Darxili will catch up, with confidence and determination to become one of the most suitable for Chinese patients.
From left to right: Professor Yu Keda, Professor Li Qian and Professor Chen Qianjun
Professor Yu Keda of fudan university affiliated cancer hospital, professor Li Qiao of cancer hospital of Chinese academy of medical sciences and professor Chen Qianjun of Guangdong Provincial Hospital of Traditional Chinese Medicine introduced experts from multiple sub-venues across the country, and everyone attended the glorious event and warmly congratulated Darsili on its successful listing.
Dai Hongbin, executive deputy general manager of Hengrui Pharmaceutical
Subsequently, Dai Hongbin, executive deputy general manager of Hengrui Pharmaceutical, pointed out in his speech that Darsili has been the result of another decade of grinding a sword for Hengrui Pharmaceutical. From the launch of the project in 2013 to the launch in 2021, Darsilli's research and development path has experienced many challenges, and its success has provided more treatment options for Chinese doctors and patients. Darsily's advanced rescue treatment and early adjuvant therapy for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and other related clinical research is advancing in an orderly manner, and in the field of HER2+ breast cancer and triple-negative breast cancer, Hengrui Pharmaceutical's many products are also being laid out, and it is believed that it will provide more and better services for the clinic.
Review the path of exploration and share the journey of the heart
Darsilli's road to R&D and go-to-market in China
The conference also traced Darcily's eight-year journey of exploration from 2013 to 2021. Li Xinyu, Deputy General Manager of Hengrui Pharmaceutical R&D Center, and Zhu Xiaoyu, Senior Medical Director, told about the mental journey with Darsili along the way, sharing unforgettable moments such as wandering when encountering difficulties and challenges, excitement when research has achieved results, joy and satisfaction when successfully listing.
100% Chinese evidence-based, closer to Chinese patients
Academician Xu Binghe
Darcily's Phase III Clinical Registration Study (DAWNA-1 Study) was named in the top international journal Nature · Nature Medicine (Impact Factor: 53.44). At the listing meeting, academician Xu Binghe, the research leader PI, comprehensively and deeply interpreted the DAWNA-1 research.
Academician Xu Binghe specifically pointed out that 100% of the patients enrolled in the DAWNA-1 study were Chinese group, 27% of the patients in the Darsilli research group had received chemotherapy in the previous rescue treatment, and 44% of the premenopausal (perimenopausal) patients were close to the current situation of breast cancer diagnosis and treatment in China.
Subsequently, Professor Ma Fei of cancer hospital of Chinese Academy of Medical Sciences, Professor Hu Xichun of the Affiliated Cancer Hospital of Fudan University, Professor Wang Xiaojia of the Affiliated Cancer Hospital of the University of Chinese Academy of Sciences, Professor Zhang Pin of the Cancer Hospital of the Chinese Academy of Medical Sciences, Professor Jin Feng of the First Affiliated Hospital of China Medical University, Professor Tong Zhongsheng of Tianjin Cancer Hospital, and Professor Wang Shusen of the Affiliated Cancer Prevention and Control Center of Sun Yat-sen University held wonderful dialogues in combination with the clinical practice of breast cancer, and elaborated on the differences between CHINESE HR+ advanced breast cancer patients and the West. Dissecting the great significance of the DAWNA-1 research based on Chinese groups, it unanimously gave a positive evaluation to Darsili.
Sail away and strive to reach more patients
In the future short drama of chasing waves, it highlights the ambition of Hengrui people to work with Chinese clinicians to open up the international market by consolidating Chinese norms.
At the meeting, Professor Jiang Zefei of the PLA General Hospital, Professor Yin Yongmei of Jiangsu Provincial People's Hospital, Professor Wu Jiong of the Affiliated Cancer Hospital of Fudan University, Professor Shao Zhimin of the Affiliated Cancer Hospital of Fudan University, Professor Zhang Qingyuan of the Affiliated Cancer Hospital of Harbin Medical University, Professor Liu Qiang of Sun Yat-sen Memorial Hospital of Sun Yat-sen University, and Professor Geng Cuizhi of the Fourth Hospital of Hebei Medical University jointly discussed medical practice, clinical research, and the future development of Chinese enterprises towards the world.
Professor Jiang Zefei and Professor Zhang Qingyuan said that under the blessing of various national policies, with the good access of drugs, the promotion of guidelines, and the tour of standardized diagnosis and treatment, the imbalance in domestic regional development will become smaller and smaller, and more and more doctors and patients can "want, afford, and use well" innovative drugs, and the overall medical level of the country will be improved.
Regarding the internationalization path of national pharmaceutical companies, Professor Jiang Zefei pointed out that there should be a more open road for internationalization, and the medical needs of different regions and different periods of time in the world are not the same. Based on China, looking at the world, not sticking to the rules, is another idea to break the situation, at the same time he also sent Hengrui's internationalization wider and wider.
Professor Liu Qiang said that in the era of great waves and sand, Hengrui Pharmaceutical should keep in mind the original intention, choose the right track, establish its own standards, and contribute to China and the world. Professor Geng Cuizhi spoke up for grassroots doctors and put forward the desire of the original research drugs to benefit more patients by entering the national medical insurance. Professor Yin Yongmei and Professor Shao Zhimin pointed out that further in-depth cooperation between scientific research or medical institutions and pharmaceutical enterprises can help the development of China's medical and health undertakings and promote the internationalization of China's wisdom. Professor Wu Jiong looks forward to the future and expects more national enterprises to focus on new targets and develop new drugs to bring long-term survival and improve the quality of life of cancer patients.
Darsilli National Listing Will push the climax in the exciting listing ceremony, many experts from various venues jointly inject energy into Darsili's listing, and the guests attending the meeting witnessed the glorious moment of Darsili's listing online and offline, officially opening China's "Da" case.
Academician Xu Binghe of the Cancer Hospital of the Chinese Academy of Medical Sciences concluded that Darsilly is currently the fourth CDK4/6 inhibitor on the market in the world, hoping to benefit more patients after the market.
Nurturing, sprouting, birth, growth, companionship, this is like an inevitable stage throughout everyone's life, February 26 Darsili National Listing Will be successfully concluded in 13 national venues, online and offline tens of thousands of people under the attention of tens of thousands of people. However, this Chinese "reach" case has just been opened, and I hope that in the future it will be more mature and write more "China reach case".